Midostaurin
- Generic Name
- Midostaurin
- Brand Names
- Rydapt
- Drug Type
- Small Molecule
- Chemical Formula
- C35H30N4O4
- CAS Number
- 120685-11-2
- Unique Ingredient Identifier
- ID912S5VON
Overview
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Background
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Indication
Investigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Associated Conditions
- Acute Myeloid Leukemia
- Aggressive Systemic Mastocytosis
- Mast Cell Leukemia (MCL)
- Systemic Mastocytosis
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.